{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:22:41Z","timestamp":1789024961125,"version":"build-2803163510"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T00:00:00Z","timestamp":1626480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T00:00:00Z","timestamp":1626480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s40263-021-00839-4","type":"journal-article","created":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T18:02:31Z","timestamp":1626544951000},"page":"1107-1122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients\u2019 Perspectives"],"prefix":"10.1007","volume":"35","author":[{"given":"Laurent M.","family":"Willems","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Rosenow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Schubert-Bast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Kurlemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann Philipp","family":"Z\u00f6llner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Bertsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Bettendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ebrahimi-Fakhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hertzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Hornemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilka","family":"Immisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Martin","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin A.","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Kluger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Knake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Knuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Marquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiltrud","family":"Muhle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"M\u00fcller-Schl\u00fcter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"von Podewils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Ruf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Ulrich","family":"Schlump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Syrbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Thiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Trollmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelheid","family":"Wiemer-Kruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Wilken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Zukunft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6288-9915","authenticated-orcid":false,"given":"Adam","family":"Strzelczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,17]]},"reference":[{"issue":"1","key":"839_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13023-019-1258-3","volume":"15","author":"JP Zollner","year":"2020","unstructured":"Z\u00f6llner JP, Franz DN, Hertzberg C, Nabbout R, Rosenow F, Sauter M, et al. A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC). Orphanet J Rare Dis. 2020;15(1):23.","journal-title":"Orphanet J Rare Dis"},{"key":"839_CR2","doi-asserted-by":"publisher","unstructured":"Strzelczyk A, Rosenow F, Z\u00f6llner JP, Simon A, Wyatt G, Holland R, Schubert-Bast S. Epidemiology, healthcare resource use, and mortality in patients with tuberous sclerosis complex: a population-based study on German health insurance data. Seizure. 2021. https:\/\/doi.org\/10.1016\/j.seizure.2021.06.027.","DOI":"10.1016\/j.seizure.2021.06.027"},{"key":"839_CR3","doi-asserted-by":"crossref","unstructured":"Chu WC, Chiang LL, Chan DC, Wong WH, Chan GC. Prevalence, mortality and healthcare economic burden of tuberous sclerosis in Hong Kong: a population-based retrospective cohort study (1995\u20132018). Orphanet J Rare Dis. 2020;15(1):264.","DOI":"10.1186\/s13023-020-01517-2"},{"issue":"1","key":"839_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1590\/1678-4685-gmb-2015-0321","volume":"40","author":"C Rosset","year":"2017","unstructured":"Rosset C, Netto CBO, Ashton-Prolla P. TSC1 and TSC2 gene mutations and their implications for treatment in tuberous sclerosis complex: a review. Genet Mol Biol. 2017;40(1):69\u201379.","journal-title":"Genet Mol Biol"},{"issue":"6","key":"839_CR5","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/sj.ejhg.5201402","volume":"13","author":"O Sancak","year":"2005","unstructured":"Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype\u2013phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur J Hum Genet. 2005;13(6):731\u201341.","journal-title":"Eur J Hum Genet"},{"issue":"10","key":"839_CR6","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.purol.2020.05.011","volume":"30","author":"P Maulaz","year":"2020","unstructured":"Maulaz P, Malinge MC, Farges D, Ingster O, Azzouzi AR, Bigot P. Prevalence of the tuberous sclerosis complex at patients taken care for a renal angiomyolipoma. Prog Urol. 2020;30(10):500\u20136.","journal-title":"Prog Urol"},{"issue":"2","key":"839_CR7","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s00246-016-1528-y","volume":"38","author":"F Aw","year":"2017","unstructured":"Aw F, Goyer I, Raboisson MJ, Boutin C, Major P, Dahdah N. Accelerated cardiac rhabdomyoma regression with everolimus in infants with tuberous sclerosis complex. Pediatr Cardiol. 2017;38(2):394\u2013400.","journal-title":"Pediatr Cardiol"},{"key":"839_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.pediatrneurol.2017.04.008","volume":"72","author":"MS Arroyo","year":"2017","unstructured":"Arroyo MS, Krueger DA, Broomall E, Stevenson CB, Franz DN. Acute management of symptomatic subependymal giant cell astrocytoma with everolimus. Pediatr Neurol. 2017;72:81\u20135.","journal-title":"Pediatr Neurol"},{"issue":"4","key":"839_CR9","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.3928\/19382359-20170320-01","volume":"46","author":"SC Randle","year":"2017","unstructured":"Randle SC. Tuberous sclerosis complex: a review. Pediatr Ann. 2017;46(4):e166\u201371.","journal-title":"Pediatr Ann"},{"issue":"7","key":"839_CR10","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","volume":"51","author":"CJ Chu-Shore","year":"2010","unstructured":"Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51(7):1236\u201341.","journal-title":"Epilepsia"},{"issue":"Pt A","key":"839_CR11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.yebeh.2017.02.007","volume":"70","author":"JK Capal","year":"2017","unstructured":"Capal JK, Bernardino-Cuesta B, Horn PS, Murray D, Byars AW, Bing NM, et al. Influence of seizures on early development in tuberous sclerosis complex. Epilepsy Behav. 2017;70(Pt A):245\u201352.","journal-title":"Epilepsy Behav"},{"issue":"Pt A","key":"839_CR12","doi-asserted-by":"publisher","first-page":"106844","DOI":"10.1016\/j.yebeh.2019.106844","volume":"103","author":"A Schoenberger","year":"2020","unstructured":"Schoenberger A, Capal JK, Ondracek A, Horn PS, Murray D, Byars AW, et al. Language predictors of autism spectrum disorder in young children with tuberous sclerosis complex. Epilepsy Behav. 2020;103(Pt A):106844.","journal-title":"Epilepsy Behav"},{"key":"839_CR13","doi-asserted-by":"crossref","unstructured":"Z\u00f6llner JP, Conradi N, Sauter M, Knuf M, Knake S, Kurlemann G, et al. Quality of life and its predictors in adults with tuberous sclerosis complex (TSC): a multicentre cohort study from Germany. Neurol Res Pract. 2021;3(1):35.","DOI":"10.1186\/s42466-021-00130-3"},{"key":"839_CR14","doi-asserted-by":"crossref","unstructured":"Grau J, Z\u00f6llner JP, Schubert-Bast S, Kurlemann G, Hertzberg C, Wiemer-Kruel A, et al. Direct and indirect costs and cost-driving factors of Tuberous sclerosis complex in children adolescents and caregivers: a multicenter cohort study. Orphanet J Rare Dis. 2021;16(1):282.","DOI":"10.1186\/s13023-021-01838-w"},{"key":"839_CR15","doi-asserted-by":"crossref","unstructured":"Z\u00f6llner JP, Grau J, Rosenow F, Sauter M, Knuf M, Kurlemann G, et al. Direct and indirect costs and cost-driving factors in adults with tuberous sclerosis complex: a multicenter cohort study and a review of the literature. Orphanet J Rare Dis. 2021;16(1):250.","DOI":"10.1186\/s13023-021-01838-w"},{"issue":"12","key":"839_CR16","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.2217\/pgs.13.143","volume":"14","author":"G Santulli","year":"2013","unstructured":"Santulli G, Totary-Jain H. Tailoring mTOR-based therapy: molecular evidence and clinical challenges. Pharmacogenomics. 2013;14(12):1517\u201326.","journal-title":"Pharmacogenomics"},{"issue":"6","key":"839_CR17","doi-asserted-by":"publisher","first-page":"e0158476","DOI":"10.1371\/journal.pone.0158476","volume":"11","author":"DN Franz","year":"2016","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost MD, Kuperman R, et al. Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study. PLoS ONE. 2016;11(6):e0158476.","journal-title":"PLoS ONE"},{"issue":"8","key":"839_CR18","doi-asserted-by":"publisher","first-page":"e0180939","DOI":"10.1371\/journal.pone.0180939","volume":"12","author":"JJ Bissler","year":"2017","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Belousova E, Frost MD, et al. Everolimus long-term use in patients with tuberous sclerosis complex: four-year update of the EXIST-2 study. PLoS ONE. 2017;12(8):e0180939.","journal-title":"PLoS ONE"},{"issue":"5","key":"839_CR19","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1212\/CPJ.0000000000000514","volume":"8","author":"DN Franz","year":"2018","unstructured":"Franz DN, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, et al. Everolimus for treatment-refractory seizures in TSC: extension of a randomized controlled trial. Neurol Clin Pract. 2018;8(5):412\u201320.","journal-title":"Neurol Clin Pract."},{"key":"839_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.yebeh.2018.05.039","volume":"91","author":"S Schubert-Bast","year":"2019","unstructured":"Schubert-Bast S, Rosenow F, Klein KM, Reif PS, Kieslich M, Strzelczyk A. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: current evidence and future perspectives. Epilepsy Behav. 2019;91:94\u20138.","journal-title":"Epilepsy Behav"},{"issue":"3","key":"839_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40272-019-00337-7","volume":"21","author":"M Bevacqua","year":"2019","unstructured":"Bevacqua M, Baldo F, Pastore S, Valencic E, Tommasini A, Maestro A, et al. Off-label use of sirolimus and everolimus in a pediatric center: a case series and review of the literature. Paediatr Drugs. 2019;21(3):185\u201393.","journal-title":"Paediatr Drugs"},{"key":"839_CR22","doi-asserted-by":"crossref","unstructured":"Willems L, Strzelczyk A, Rosenow F. Everolimus as disease-specific treatment option in tuberous sclerosis complex-associated drug refractory epilepsy:a systematic review. Z Epileptol. 2021;34:168\u201374.","DOI":"10.1007\/s10309-020-00393-x"},{"issue":"4","key":"839_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):243\u201354.","journal-title":"Pediatr Neurol"},{"issue":"10","key":"839_CR24","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","volume":"4","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296.","journal-title":"PLoS Med"},{"issue":"9","key":"839_CR25","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1111\/epi.13089","volume":"56","author":"J Riechmann","year":"2015","unstructured":"Riechmann J, Strzelczyk A, Reese JP, Boor R, Stephani U, Langner C, et al. Costs of epilepsy and cost-driving factors in children, adolescents, and their caregivers in Germany. Epilepsia. 2015;56(9):1388\u201397.","journal-title":"Epilepsia"},{"issue":"4","key":"839_CR26","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.yebeh.2012.01.021","volume":"23","author":"A Strzelczyk","year":"2012","unstructured":"Strzelczyk A, Nickolay T, Bauer S, Haag A, Knake S, Oertel WH, et al. Evaluation of health-care utilization among adult patients with epilepsy in Germany. Epilepsy Behav. 2012;23(4):451\u20137.","journal-title":"Epilepsy Behav"},{"issue":"8","key":"839_CR27","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1111\/epi.16099","volume":"60","author":"A Strzelczyk","year":"2019","unstructured":"Strzelczyk A, Schubert-Bast S, Bast T, Bettendorf U, Fiedler B, Hamer HM, et al. A multicenter, matched case-control analysis comparing burden-of-illness in Dravet syndrome to refractory epilepsy and seizure remission in patients and caregivers in Germany. Epilepsia. 2019;60(8):1697\u2013710.","journal-title":"Epilepsia"},{"issue":"3","key":"839_CR28","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ejpn.2019.02.014","volume":"23","author":"A Strzelczyk","year":"2019","unstructured":"Strzelczyk A, Kalski M, Bast T, Wiemer-Kruel A, Bettendorf U, Kay L, et al. Burden-of-illness and cost-driving factors in Dravet syndrome patients and carers: a prospective, multicenter study from Germany. Eur J Paediatr Neurol. 2019;23(3):392\u2013403.","journal-title":"Eur J Paediatr Neurol"},{"issue":"6","key":"839_CR29","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.yebeh.2004.08.001","volume":"5","author":"M Privitera","year":"2004","unstructured":"Privitera M, Ficker DM. Assessment of adverse events and quality of life in epilepsy: design of a new community-based trial. Epilepsy Behav. 2004;5(6):841\u20136.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"839_CR30","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.yebeh.2008.02.006","volume":"13","author":"M Carreno","year":"2008","unstructured":"Carreno M, Gil-Nagel A, Sanchez JC, Elices E, Serratosa JM, Salas-Puig J, et al. Strategies to detect adverse effects of antiepileptic drugs in clinical practice. Epilepsy Behav. 2008;13(1):178\u201383.","journal-title":"Epilepsy Behav"},{"issue":"5","key":"839_CR31","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343.","journal-title":"Ann Med"},{"issue":"5","key":"839_CR32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1023\/A:1008853819715","volume":"7","author":"U Ravens-Sieberer","year":"1998","unstructured":"Ravens-Sieberer U, Bullinger M. Assessing health-related quality of life in chronically ill children with the German KINDL: first psychometric and content analytical results. Qual Life Res. 1998;7(5):399\u2013407.","journal-title":"Qual Life Res"},{"key":"839_CR33","doi-asserted-by":"crossref","unstructured":"Riechmann J, Willems LM, Boor R, Kieslich M, Knake S, Langner C, et al. Quality of life and correlating factors in children adolescents with epilepsy and their caregivers: A cross-sectional multicenter study from Germany. Seizure. 2019;69:92\u201398.","DOI":"10.1016\/j.seizure.2019.03.016"},{"issue":"1","key":"839_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/biostatistics\/kxw030","volume":"18","author":"Y Benjamini","year":"2017","unstructured":"Benjamini Y, Cohen R. Weighted false discovery rate controlling procedures for clinical trials. Biostatistics. 2017;18(1):91\u2013104.","journal-title":"Biostatistics"},{"issue":"1","key":"839_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/biostatistics\/kxt032","volume":"15","author":"Y Benjamini","year":"2014","unstructured":"Benjamini Y, Hechtlinger Y. Discussion: an estimate of the science-wise false discovery rate and applications to top medical journals by Jager and Leek. Biostatistics. 2014;15(1):13\u20136.","journal-title":"Biostatistics"},{"key":"839_CR36","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1080\/02664760220136168","volume":"29","author":"A Agostinelli","year":"2002","unstructured":"Agostinelli A. Robust stepwise regression. J Appl Stat. 2002;29:825\u201340.","journal-title":"J Appl Stat"},{"issue":"1","key":"839_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13023-018-0775-9","volume":"13","author":"Y Zhan","year":"2018","unstructured":"Zhan Y, Shen L, Xu W, Wu X, Zhang W, Wang J, et al. Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study. Orphanet J Rare Dis. 2018;13(1):34.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"839_CR38","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13023-018-0915-2","volume":"13","author":"L Zhou","year":"2018","unstructured":"Zhou L, Ouyang R, Luo H, Ren S, Chen P, Peng Y, et al. Efficacy of sirolimus for the prevention of recurrent pneumothorax in patients with lymphangioleiomyomatosis: a case series. Orphanet J Rare Dis. 2018;13(1):168.","journal-title":"Orphanet J Rare Dis"},{"issue":"17","key":"839_CR39","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","volume":"364","author":"FX McCormack","year":"2011","unstructured":"McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595\u2013606.","journal-title":"N Engl J Med"},{"key":"839_CR40","unstructured":"European Medicines Agency. EU\/3\/10\/764: EMA statement on the use of everolimus in TSC; 2018."},{"key":"839_CR41","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.urology.2016.04.027","volume":"95","author":"J Bissler","year":"2016","unstructured":"Bissler J, Cappell K, Charles H, Song X, Liu Z, Prestifilippo J, et al. Long-term clinical morbidity in patients with renal angiomyolipoma associated with tuberous sclerosis complex. Urology. 2016;95:80\u20137.","journal-title":"Urology"},{"issue":"7","key":"839_CR42","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1080\/03007995.2017.1313726","volume":"33","author":"X Song","year":"2017","unstructured":"Song X, Liu Z, Cappell K, Gregory C, Said Q, Prestifilippo J, et al. Natural history of patients with tuberous sclerosis complex related renal angiomyolipoma. Curr Med Res Opin. 2017;33(7):1277\u201382.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"839_CR43","doi-asserted-by":"publisher","first-page":"e1335","DOI":"10.1542\/peds.2010-2910","volume":"127","author":"D Tiberio","year":"2011","unstructured":"Tiberio D, Franz DN, Phillips JR. Regression of a cardiac rhabdomyoma in a patient receiving everolimus. Pediatrics. 2011;127(5):e1335\u20137.","journal-title":"Pediatrics"},{"issue":"1","key":"839_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/apc.APC_79_18","volume":"12","author":"B Dhulipudi","year":"2019","unstructured":"Dhulipudi B, Bhakru S, Rajan S, Doraiswamy V, Koneti NR. Symptomatic improvement using everolimus in infants with cardiac rhabdomyoma. Ann Pediatr Cardiol. 2019;12(1):45\u20138.","journal-title":"Ann Pediatr Cardiol"},{"issue":"6","key":"839_CR45","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.ejpn.2018.06.007","volume":"22","author":"DA Krueger","year":"2018","unstructured":"Krueger DA, Capal JK, Curatolo P, Devinsky O, Ess K, Tzadok M, et al. Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): multicentre clinical experience. Eur J Paediatr Neurol. 2018;22(6):1066\u201373.","journal-title":"Eur J Paediatr Neurol"},{"issue":"7","key":"839_CR46","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jamadermatol.2018.0465","volume":"154","author":"TN Darling","year":"2018","unstructured":"Darling TN. Topical sirolimus to treat tuberous sclerosis complex (TSC). JAMA Dermatol. 2018;154(7):761\u20132.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"839_CR47","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jaad.2015.07.018","volume":"73","author":"N Nathan","year":"2015","unstructured":"Nathan N, Wang JA, Li S, Cowen EW, Haughey M, Moss J, et al. Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus. J Am Acad Dermatol. 2015;73(5):802\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"839_CR48","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1111\/jdv.14964","volume":"32","author":"DN Franz","year":"2018","unstructured":"Franz DN, Budde K, Kingswood JC, Belousova E, Sparagana S, de Vries PJ, et al. Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies. J Eur Acad Dermatol Venereol. 2018;32(10):1796\u2013803.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"20","key":"839_CR49","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1146\/annurev-genom-083118-015354","volume":"31","author":"CL Salussolia","year":"2019","unstructured":"Salussolia CL, Klonowska K, Kwiatkowski DJ, Sahin M. Genetic etiologies, diagnosis, and treatment of tuberous sclerosis complex. Annu Rev Genomics Hum Genet. 2019;31(20):217\u201340.","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"6","key":"839_CR50","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ejpn.2013.06.002","volume":"17","author":"G Wiegand","year":"2013","unstructured":"Wiegand G, May TW, Ostertag P, Boor R, Stephani U, Franz DN. Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option? Eur J Paediatr Neurol. 2013;17(6):631\u20138.","journal-title":"Eur J Paediatr Neurol"},{"issue":"10056","key":"839_CR51","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10056):2153\u201363.","journal-title":"Lancet"},{"issue":"6","key":"839_CR52","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","volume":"80","author":"DA Krueger","year":"2013","unstructured":"Krueger DA, Care MM, Agricola K, Tudor C, Mays M, Franz DN. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology. 2013;80(6):574\u201380.","journal-title":"Neurology"},{"issue":"1","key":"839_CR53","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13023-016-0530-z","volume":"11","author":"S Samueli","year":"2016","unstructured":"Samueli S, Abraham K, Dressler A, Groppel G, Muhlebner-Fahrngruber A, Scholl T, et al. Efficacy and safety of everolimus in children with TSC-associated epilepsy: pilot data from an open single-center prospective study. Orphanet J Rare Dis. 2016;11(1):145.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"839_CR54","first-page":"A5582","volume":"66","author":"EMM Svarrer","year":"2019","unstructured":"Svarrer EMM, Fischer CM, Frederiksen MG, Born AP, Hoei-Hansen CE. Everolimus as adjunctive treatment in tuberous sclerosis complex-associated epilepsy in children. Dan Med J. 2019;66(12):A5582.","journal-title":"Dan Med J"},{"key":"839_CR55","doi-asserted-by":"publisher","first-page":"107182","DOI":"10.1016\/j.yebeh.2020.107182","volume":"111","author":"NE Kadish","year":"2020","unstructured":"Kadish NE, Riedel C, Stephani U, Wiegand G. Developmental outcomes in children\/adolescents and one adult with tuberous sclerosis complex (TSC) and refractory epilepsy treated with everolimus. Epilepsy Behav. 2020;111:107182.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"839_CR56","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13023-019-1077-6","volume":"14","author":"A Saffari","year":"2019","unstructured":"Saffari A, Brosse I, Wiemer-Kruel A, Wilken B, Kreuzaler P, Hahn A, et al. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age: a multicenter retrospective study. Orphanet J Rare Dis. 2019;14(1):96.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"839_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.braindev.2018.07.003","volume":"41","author":"M Mizuguchi","year":"2019","unstructured":"Mizuguchi M, Ikeda H, Kagitani-Shimono K, Yoshinaga H, Suzuki Y, Aoki M, et al. Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan. Brain Dev. 2019;41(1):1\u201310.","journal-title":"Brain Dev"},{"key":"839_CR58","doi-asserted-by":"crossref","unstructured":"Stockinger J, Strzelczyk A, Nemecek A, Cicanic M, B\u00f6sebeck F, Brandt C, et al. Everolimus in adult tuberous sclerosis complex patients with epilepsy: too late for success? A retrospective study. Epilepsia. 2021;62(3):785\u201394.","DOI":"10.1111\/epi.16829"},{"issue":"5","key":"839_CR59","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ejpn.2018.05.006","volume":"22","author":"P Curatolo","year":"2018","unstructured":"Curatolo P, Nabbout R, Lagae L, Aronica E, Ferreira JC, Feucht M, et al. Management of epilepsy associated with tuberous sclerosis complex: updated clinical recommendations. Eur J Paediatr Neurol. 2018;22(5):738\u201348.","journal-title":"Eur J Paediatr Neurol"},{"issue":"18","key":"839_CR60","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1080\/14656566.2020.1803830","volume":"21","author":"A Strzelczyk","year":"2020","unstructured":"Strzelczyk A, Mann C, Willems LM, Rosenow F, Bauer S. Cenobamate for the treatment of focal epilepsies. Expert Opin Pharmacother. 2020;21(18):2215\u201323.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"839_CR61","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1586\/17512433.2016.1156529","volume":"9","author":"A Strzelczyk","year":"2016","unstructured":"Strzelczyk A, Klein KM, Willems LM, Rosenow F, Bauer S. Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol. 2016;9(5):637\u201345.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"839_CR62","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1111\/epi.13768","volume":"58","author":"A Strzelczyk","year":"2017","unstructured":"Strzelczyk A, Steinig I, von Podewils F, Moddel G, Bauer S, Klein KM, et al. Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicentre cohort study from Germany. Epilepsia. 2017;58(7):1208\u201316.","journal-title":"Epilepsia"},{"issue":"14","key":"839_CR63","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1080\/14656566.2019.1637420","volume":"20","author":"LM Willems","year":"2019","unstructured":"Willems LM, Bauer S, Rosenow F, Strzelczyk A. Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus. Expert Opin Pharmacother. 2019;20(14):1755\u201365.","journal-title":"Expert Opin Pharmacother"},{"key":"839_CR64","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3389\/fneur.2018.00569","volume":"9","author":"LM Willems","year":"2018","unstructured":"Willems LM, Bertsche A, Bosebeck F, Hornemann F, Immisch I, Klein KM, et al. Efficacy, retention, and tolerability of brivaracetam in patients with epileptic encephalopathies: a multicenter cohort study from Germany. Front Neurol. 2018;9:569.","journal-title":"Front Neurol"},{"issue":"6","key":"839_CR65","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1586\/17512433.2015.1091303","volume":"8","author":"A Strzelczyk","year":"2015","unstructured":"Strzelczyk A, Willems LM, Willig S, Rosenow F, Bauer S. Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol. 2015;8(6):733\u201340.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"839_CR66","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/17512433.2018.1421066","volume":"11","author":"LM Willems","year":"2018","unstructured":"Willems LM, Z\u00f6llner JP, Paule E, Schubert-Bast S, Rosenow F, Strzelczyk A. Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: systematic review of current evidence. Expert Rev Clin Pharmacol. 2018;11(3):309\u201324.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"839_CR67","doi-asserted-by":"crossref","unstructured":"Menzler K, Mross PM, Rosenow F, Schubert-Bast S, Willems LM, Zahnert F, et al. First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study. BMJ Open 2019;9(11):e030746.","DOI":"10.1136\/bmjopen-2019-030746"},{"key":"839_CR68","doi-asserted-by":"crossref","unstructured":"Schubert-Bast S, Willems LM, Kurlemann G, Knake S, M\u00fcller-Schl\u00fcter K, Rosenow F, Strzelczyk A. Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents. Epilepsy Behav. 2018;89:89-93.","DOI":"10.1016\/j.yebeh.2018.10.018"},{"key":"839_CR69","doi-asserted-by":"crossref","unstructured":"Strzelczyk A, Kay L, Bauer S, Immisch I, Klein KM, Knake S, et al. Use of brivaracetam in genetic generalized epilepsies and for acute intravenous treatment of absence status epilepticus. Epilepsia. 2018;59(8):1549-1556.","DOI":"10.1111\/epi.14476"},{"key":"839_CR70","doi-asserted-by":"publisher","unstructured":"L\u00f6scher W, Klein P. The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. CNS Drugs. 2021. https:\/\/doi.org\/10.1007\/s40263-021-00827-8.","DOI":"10.1007\/s40263-021-00827-8"},{"issue":"12","key":"839_CR71","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00381-013-2170-0","volume":"29","author":"AM Cappellano","year":"2013","unstructured":"Cappellano AM, Senerchia AA, Adolfo F, Paiva PM, Pinho R, Covic A, et al. Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex. Childs Nerv Syst. 2013;29(12):2301\u20135.","journal-title":"Childs Nerv Syst"},{"issue":"1","key":"839_CR72","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2165\/11207730-000000000-00000","volume":"14","author":"MP Curran","year":"2012","unstructured":"Curran MP. Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Paediatr Drugs. 2012;14(1):51\u201360.","journal-title":"Paediatr Drugs"},{"issue":"6","key":"839_CR73","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/ana.24523","volume":"78","author":"DN Franz","year":"2015","unstructured":"Franz DN, Agricola K, Mays M, Tudor C, Care MM, Holland-Bouley K, et al. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. Ann Neurol. 2015;78(6):929\u201338.","journal-title":"Ann Neurol"},{"issue":"1","key":"839_CR74","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10147-020-01792-w","volume":"26","author":"T Hatano","year":"2021","unstructured":"Hatano T, Endo K, Tamari M. Efficacy and safety of low-dose everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex. Int J Clin Oncol. 2021;26(1):163\u20138.","journal-title":"Int J Clin Oncol"},{"key":"839_CR75","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jpeds.2017.06.076","volume":"190","author":"N Dahdah","year":"2017","unstructured":"Dahdah N. Everolimus for the treatment of tuberous sclerosis complex-related cardiac rhabdomyomas in pediatric patients. J Pediatr. 2017;190:21-6.e7.","journal-title":"J Pediatr"},{"issue":"7","key":"839_CR76","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1017\/S1047951118000598","volume":"28","author":"A Martinez-Garcia","year":"2018","unstructured":"Martinez-Garcia A, Michel-Macias C, Cordero-Gonzalez G, Escamilla-Sanchez KI, Aguinaga-Rios M, Coronado-Zarco A, et al. Giant left ventricular rhabdomyoma treated successfully with everolimus: case report and review of literature. Cardiol Young. 2018;28(7):903\u20139.","journal-title":"Cardiol Young"},{"issue":"10","key":"839_CR77","doi-asserted-by":"publisher","first-page":"e4562","DOI":"10.1097\/MD.0000000000004562","volume":"96","author":"S Wahid","year":"2017","unstructured":"Wahid S, Chiang PC, Luo HL, Huang SC, Tsai EM, Chiang PH. Pelvic lymphangioleiomyomatosis treated successfully with everolimus: two case reports with literature review. Medicine (Baltimore). 2017;96(10):e4562.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"839_CR78","doi-asserted-by":"publisher","first-page":"1618661","DOI":"10.1080\/20016689.2019.1618661","volume":"7","author":"N Germain","year":"2019","unstructured":"Germain N, Aballea S, Toumi M. Measuring the health-related quality of life in young children: how far have we come? J Mark Access Health Policy. 2019;7(1):1618661.","journal-title":"J Mark Access Health Policy."},{"issue":"10","key":"839_CR79","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/S1470-2045(17)30471-0","volume":"18","author":"ME Pavel","year":"2017","unstructured":"Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, et al. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(10):1411\u201322.","journal-title":"Lancet Oncol"},{"issue":"1","key":"839_CR80","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13023-017-0581-9","volume":"12","author":"M Davies","year":"2017","unstructured":"Davies M, Saxena A, Kingswood JC. Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide. Orphanet J Rare Dis. 2017;12(1):35.","journal-title":"Orphanet J Rare Dis"},{"key":"839_CR81","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jpeds.2016.01.027","volume":"172","author":"S Jozwiak","year":"2016","unstructured":"Jozwiak S, Kotulska K, Berkowitz N, Brechenmacher T, Franz DN. Safety of everolimus in patients younger than 3 years of age: results from EXIST-1, a randomized, controlled clinical trial. J Pediatr. 2016;172:151-5.e1.","journal-title":"J Pediatr"},{"issue":"6","key":"839_CR82","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/bcp.13067","volume":"82","author":"DB Hawcutt","year":"2016","unstructured":"Hawcutt DB, Russell NJ, Maqsood H, Kouranloo K, Gomberg S, Waitt C, et al. Spontaneous adverse drug reaction reports for neonates and infants in the UK 2001\u20132010: content and utility analysis. Br J Clin Pharmacol. 2016;82(6):1601\u201312.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"839_CR83","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ejpn.2018.01.027","volume":"22","author":"VA Bach","year":"2018","unstructured":"Bach VA, Neininger MP, Spindler UP, Hotopp LC, Hornemann F, Syrbe S, et al. How do parents perceive adverse drug events of their children\u2019s anticonvulsant medication? Eur J Paediatr Neurol. 2018;22(3):427\u201333.","journal-title":"Eur J Paediatr Neurol"},{"issue":"23","key":"839_CR84","first-page":"393","volume":"115","author":"D Dubrall","year":"2018","unstructured":"Dubrall D, Schmid M, Alesik E, Paeschke N, Stingl J, Sachs B. Frequent adverse drug reactions, and medication groups under suspicion. Dtsch Arztebl Int. 2018;115(23):393\u2013400.","journal-title":"Dtsch Arztebl Int"},{"issue":"2","key":"839_CR85","doi-asserted-by":"publisher","first-page":"74","DOI":"10.14581\/jer.18012","volume":"8","author":"OY Kwon","year":"2018","unstructured":"Kwon OY, Park SP. Validity of the Liverpool Adverse Events Profile as a screening tool for detecting comorbid depression or anxiety disorder in people with epilepsy. J Epilepsy Res. 2018;8(2):74\u201380.","journal-title":"J Epilepsy Res."},{"issue":"8","key":"839_CR86","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1016\/j.transproceed.2010.07.083","volume":"42","author":"AI Sanchez-Fructuoso","year":"2010","unstructured":"Sanchez-Fructuoso AI, Ruiz JC, Perez-Flores I, Gomez Alamillo C, Calvo Romero N, Arias M. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus. Transplant Proc. 2010;42(8):3050\u20132.","journal-title":"Transplant Proc"},{"key":"839_CR87","first-page":"347","volume":"30","author":"P Sedgwick","year":"2013","unstructured":"Sedgwick P. Questionnaire surveys: sources of bias. BMJ. 2013;30:347.","journal-title":"BMJ"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00839-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00839-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00839-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T11:21:26Z","timestamp":1632828086000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00839-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,17]]},"references-count":87,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["839"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00839-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,17]]},"assertion":[{"value":"21 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt\nDEAL. This work was supported by the federal state Hessen with a LOEWE grant to the Center of Personal and Translational Epilepsy Research (CePTER).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Laurent M. Willems has no conflicts of interest that are directly relevant to the content of this article. Felix Rosenow reports personal fees from Arvelle Therapeutics, Eisai GmbH, GW Pharmaceuticals, Novartis, Medtronic, and UCB and grants from the Detlev-Wrobel-Fonds for Epilepsy Research, the Deutsche Forschungsgemeinschaft, the LOEWE Programme of the State of Hesse and the European Union. Susanne Schubert-Bast reports personal fees from Eisai, Desitin Pharma, GW Pharmaceuticals companies, LivaNova, UCB and Zogenix. Gerhard Kurlemann reports personal fees from Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, UCB, Novartis, Takeda and Zogenix. Johann Philipp Z\u00f6llner reports speakers\u2019 honoraria and travel grants from Eisai and Desitin Arzneimittel. Thomas Bast reports personal fees from Eisai, Desitin Arzneimittel, GW Pharma, Novartis, Nutricia, Shire, Takeda, UCB Pharma and Zogenix. Astrid Bertsche reports personal fees from Desitin Arzneimittel GmbH, Eisai GmbH, GW Pharma GmbH, Shire\/Takeda GmbH, UCB Pharma GmbH and ViroPharma GmbH. Daniel Ebrahimi-Fakhari reports personal fees from GW Pharmaceuticals companies. Christoph Hertzberg reports personal fees from Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, Novartis, Shire and Zogenix. Ilka Immisch reports personal fees from UCB Pharma GmbH. Julia Jacobs reports personal fees from Eisai, GW Pharmaceuticals companies and Zogenix and has been supported by the German Research Foundation (DFG; JA 1725\/4-1). Karl Martin Klein reports personal fees from UCB Pharma, Novartis Pharma AG, Eisai and GW Pharmaceuticals, grants from the federal state Hessen through the LOEWE program and grants from the Canadian Institutes of Health Research. Kerstin A. Klotz reports personal fees from GW Pharmaceuticals companies and Zogenix and was supported by the Berta-Ottenstein-Program for Clinician Scientists from the Faculty of Medicine, University of Freiburg. Gerhard Kluger reports personal fees from Desitin Arzneimittel, Eisai and Zogenix. Susanne Knake reports speaker\u2019s honoraria from Arvelle, Eisai, Epilog and UCB. Thomas Mayer reports personal fees and grants from Arvelle Therapeutics, Eisai, GW Pharmaceuticals companies, UCB and Zogenix. Sascha Meyer reports grants from Novartis, UCB, Shire, Deutsche Forschungsgemeinschaft and Epilepsiestiftung Dr. Wolf. Hiltrud Muhle reports personal fees from Desitin Arzneimittel, UCB, Novartis and Zogenix. Karen M\u00fcller-Schl\u00fcter reports personal fees from Nutricia, Desitin Arzneimittel, Shire, Medice, Novartis and UCB. Felix von Podewils reports personal fees and grants from Bial, Desitin Arzneimittel, Eisai, GW Pharmaceutical companies, Arvelle Therapeutics, Zogenix and UCB Pharma. Matthias Sauter reports personal fees from Novartis and GW Pharmaceuticals companies. Regina Trollmann reports personal fees from Eisai, Desitin, PTC Therapetics, Roche and Sanofi Genzyme. Adelheid Wiemer-Kruel reports personal fees from Desitin Arzneimittel, GW Pharmaceuticals companies, Nutricia GmbH, Vitaflo and UCB. Bernd Wilken reports fees and compensation for travel expenses from Eisai, Takeda\/Shire, Ipsen and PharmAllergan. Adam Strzelczyk reports personal fees and grants from Arvelle Therapeutics, Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, LivaNova, Marinus Pharma, Medtronic, UCB and Zogenix. Ulrich Bettendorf, Janina Grau, Andreas Hahn, Hans Hartmann, Frauke Hornemann, Markus Knuf, Klaus Marquard, Susanne Ruf, Hannah Sch\u00e4fer, Jan-Ulrich Schlump, Steffen Syrbe, Charlotte Thiels and Bianca Zukunft have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study received the approval of the local Ethics Committee of Goethe-University, Frankfurt am Main, Germany.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent by the patient or legal guardian was mandatory to participate in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All participants in the study or their legal guardians consented to the publication of the collected data in an anonymised form when they were included in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Anonymised data will be made available on reasonable request, with respect to the German General Data Protection Regulation (Datenschutz-Grundverordnung, DGSVO).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"LMW, FR, SSB, GKu and AS developed the idea for this analysis. LMW and AS conceived the paper, performed the statistical analysis and wrote the first draft. LMW, FR, SSB, GKu, JPZ, TB, AB, UB, DEF, JG, AH, HH, CH, FH, II, JJ, KMK, KAK, GKl, SK, MK, KM, TM, SM, HM, KMS, FvP, SR, MS, HS, JUS, SSy, CT, RT, AWK, BW, BZ and AS acquired patient data, edited the manuscript and discussed the results. LMW created the charts and figures. All authors contributed to the final manuscript, approved the final manuscript for publication and agree to be accountable for the work presented in the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}